AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update - Endorsed by the National Heart, Lung, and Blood Institute
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update - Endorsed by the National Heart, Lung, and Blood Institute
复制标题
DOI：
10.1161/circulationaha.106.174516
复制
发表时间：
2006-05-16
期刊：
影响因子：
37.8
通讯作者：
Taubert, Kathryn A.
中科院分区：
文献类型：
--
作者：
Smith, Sidney C., Jr.;Allen, Jerilyn;Taubert, Kathryn A.
自 2001 年更新美国心脏协会 (AHA)/美国心脏病学会 (ACC) 关于二级预防的共识声明以来，(1) 来自临床试验的重要证据进一步支持和扩大了针对患有冠状动脉和其他动脉粥样硬化血管疾病（包括外周动脉疾病、动脉粥样硬化主动脉疾病和颈动脉疾病）的患者进行积极的风险降低治疗的优点。越来越多的证据证实，积极的综合风险因素管理可以提高生存率，减少复发事件和介入手术的需要，并提高这些患者的生活质量。
Since the 2001 update of the American Heart Association (AHA)/American College of Cardiology (ACC) consensus statement on secondary prevention,(1) important evidence from clinical trials has emerged that further supports and broadens the merits of aggressive risk-reduction therapies for patients with established coronary and other atherosclerotic vascular disease, including peripheral arterial disease, atherosclerotic aortic disease, and carotid artery disease. This growing body of evidence confirms that aggressive comprehensive risk factor management improves survival, reduces recurrent events and the need for interventional procedures, and improves quality of life for these patients.